Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1752-1947
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature ; volume:12 ; number:1 ; day:30 ; month:5 ; year:2018 ; pages:1-6 ; date:12.2018
Journal of medical case reports ; 12, Heft 1 (30.5.2018), 1-6, 12.2018

Urheber
Nagaharu, Keiki
Beteiligte Personen und Organisationen
Masuya, Masahiro
Kageyama, Yuki
Yamaguchi, Takanori
Ito, Ryugo
Kawakami, Keiki
Ito, Masafumi
Katayama, Naoyuki
SpringerLink (Online service)

DOI
10.1186/s13256-018-1693-0
URN
urn:nbn:de:101:1-2018080321513728871445
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:23 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Nagaharu, Keiki
  • Masuya, Masahiro
  • Kageyama, Yuki
  • Yamaguchi, Takanori
  • Ito, Ryugo
  • Kawakami, Keiki
  • Ito, Masafumi
  • Katayama, Naoyuki
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin

Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom

Brentuximab Vedotin als Erstlinientherapie : Hodgkin-Lymphom

Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review

Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review

Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report

Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report

Autologous bone marrow transplantation for Hodgkin's disease, non-Hodgkin's lymphoma and multiple myeloma

Konferenzschrift | Kongress

Autologous bone marrow transplantation for Hodgkin's disease, non-Hodgkin's lymphoma and multiple myeloma

Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma

Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma

Cutaneous Hodgkin’s lymphoma

Cutaneous Hodgkin’s lymphoma

Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin

Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin

Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma

Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

Verbundene Objekte